ArticleSouth Asian journal of cancer2025
CD20-Negative Primary Bone Marrow Large B Cell Lymphoma: A Report of Two Cases with Review of Literature.
Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary adrenal CD20-negative diffuse large B-cell lymphoma: Diagnostic and therapeutic challenges-A case report.Radiology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe diagnostic and therapeutic challenges in this rare entity of CD20-negative B cell lymphomas. They comprise only 1 to 2% of all B cell lymphoma with four subcategories. However, with an increasing understanding of these cases, novel entities have been recognized. Workup, treatment, and follow-up of two CD20-negative B cell lymphoma cases, including a novel entity, have been described. A novel case of triple expresser CD20-negative B cell lymphoma and plasmablastic lymphoma has been diagnosed. The absence of CD20 leads to the abolishment of the targeted drug (rituximab) from the treatment regimen. These cases render the importance of extensive immunohistochemistry and fluorescence in situ hybridization workup for diagnosis of this rare entity. Treatment also remains a challenge as immunotherapy with CD20-targeted drugs cannot be given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.